Beyond tirzepatide, other incretin-based therapies have shown promise, such as retatrutide, a novel triple-hormone receptor agonist that simultaneously activates GLP-1, GIP, and glucagon receptors, with early-phase trials demonstrating profound effects on weight reduction [36]
Slower titration schedules may reduce early GI side effects
Why are gray-market retatrutide products risky
GSH levels are found to be elevated in illness/cancers such as Alzheimers disease 8 as well as ovarian 9 , liver 3 , lung, colorectal, breast, head and neck cancer patients 10
| 2024 Edition The sale of research peptides is loosely regulated across the English-speaking world, and many companies sell substandard imported products